| 40th week of 2008 patent applcation highlights part 68 |
| Patent application number | Title | Published |
|---|
| 20080242550 | TUNABLE FILTER AND METHOD FOR FABRICATING THE SAME - The tunable filter includes two or more adjacent resonators, and a variable capacitive coupler formed on the same substrate where the resonators are formed provided between the resonators. The tunable filter is appropriate for integration which can efficiently change a coupling capacitance between the resonators using a simple structure. | 2008-10-02 |
| 20080242551 | Wire-in-conduit magnetic conductor technology - A new type of conductor well-suited for use in a superconducting electromagnet. The conductor comprises a single electrically conductive member at its core. The conductor may include concentric layers of dissimilar materials. This conductor is surrounded by a channel through which coolant—typically liquid helium—can flow. The channel is bounded by a metal conduit of sufficient strength to withstand the Lorentz forces. The metal conduit is covered by an insulator which forces the current into the desired helical path. | 2008-10-02 |
| 20080242552 | MOLECULAR RECOGNITION OF MATERIALS - The present invention includes methods for selective binding of inorganic materials and the compositions that made up of the selecting agent and the target materials. One form of the present invention is a method for selecting crystal-binding peptides with binding specificity including the steps of contacting one or more amino acid oligomers with one or more single-crystals of a semiconductor material so that the oligomers may bind to the crystal and eluting the bound amino acid oligomers from the single-crystals. | 2008-10-02 |
| 20080242553 | Devices and methods for biochip multiplexing - The invention is directed to devices that allow for simultaneous multiple biochip analysis. In particular, the devices are configured to hold multiple cartridges comprising biochips comprising arrays such as nucleic acid arrays, and allow for high throughput analysis of samples. | 2008-10-02 |
| 20080242554 | NUCLEOTIDE PRIMER SET AND NUCLEOTIDE PROBE FOR DETECTING GENOTYPE OF METHYLENE TETRAHYDROFOLATE REDUCTASE (MTHFR) - There is provided is a nucleotide primer set for LAMP amplification used for detecting genotypes of single-nucleotide polymorphisms C677T and A1298C of an MTHFR gene. There is also provided a nucleotide probe for detecting an amplification product amplified by the primer set according to the present invention. There is also provided a method of detecting the genotypes of the single-nucleotide polymorphisms C677T and A1298C in the MTHFR gene, by using the primer set according to the present invention. | 2008-10-02 |
| 20080242555 | MULTIPLEX NUCLEIC ACID REACTIONS - The invention is directed to a variety of multiplexing methods used to amplify and/or genotype a variety of samples simultaneously. | 2008-10-02 |
| 20080242556 | METHODS OF MACROMOLECULAR ANALYSIS USING NANOCHANNEL ARRAYS - Methods of analyzing features such as the physical size of macromolecules or biomarkers along large genomic DNA molecules were disclosed as well as the devices for carrying out such high throughput analysis in a massively parallel fashion. Methods of fabricating such devices are also disclosed. | 2008-10-02 |
| 20080242557 | System For Detecting Molecular Interactions - This invention relates to a method for detecting interactions between molecules, such as, biomolecules, and relates to a method for screening target molecules, both in vivo and in vitro. In this invention, the first detecting material and the second detecting material are provided, wherein the first detecting material is bound to a localizer which is translocated by externally applied driving force, and the second detecting material is bound to a label. Thus, the complex of the first detecting material and the second detecting material can be detected reversibly by changing the strength of the externally applied driving force, and the target molecule can be screened effectively. | 2008-10-02 |
| 20080242558 | FABRICATED BIOFILM STORAGE DEVICE - The present invention includes a method and composition of storing and preserving biofilms for input and output of high-density information. One form of the present invention is a fabricated biofilm storage device with a biologic material applied to a substrate to form, e.g., a dry thin film stable at room temperature for extended periods of time. Another form of the present invention is a method of fabricating a biofilm storage device in which a biologic material is applied to a substrate under conditions that promote alignment of the biologic material on the substrate. The composition, method, and kit of the present invention have universal application in biologics, magnetics, optics and microelectronics. | 2008-10-02 |
| 20080242559 | Protein and peptide arrays - Ultrahigh resolution patterning, preferably carried out by DIP PEN™ nanolithographic printing, can be used to construct peptide and protein nanoarrays with nanometer-level dimensions. The peptide and protein nanoarrays, for example, exhibit almost no detectable nonspecific binding of proteins to their passivated portions. This work demonstrates how DIP PEN™ nanolithographic printing can be used in a method to generate high density protein and peptide patterns, which exhibit bioactivity and virtually no non-specific adsorption. It also shows that one can use AFM-based screening procedures to study the reactivity of the features that comprise such nanoarrays. The method encompasses a wide range of protein and peptide structures including, for example, enzymes and antibodies. Features at or below 300 nm can be achieved. In a preferred embodiment, parallel printing with multipen systems are used. | 2008-10-02 |
| 20080242560 | METHODS FOR GENERATING AMPLIFIED NUCLEIC ACID ARRAYS - The present invention relates to methods for generating an array of amplified nucleic acid sequences. The methods can utilize amplicons that form nucleic acid balls that can be arrayed on a solid support. The invention additionally provides methods for obtaining targeted nucleic acid sequences. | 2008-10-02 |
| 20080242561 | MASSIVELY PARALLEL SYNTHESIS OF BIOPOLYMERIC ARRAYS - Methods for fabricating dense arrays of polymeric molecules in a highly multiplexed manner are provided using semiconductor-processing-derived lithographic methods. Advantageously, the methods are adaptable to the synthesis of a variety of polymeric compounds. For example, arrays of branched peptides and polymers joined by peptide bonds may be fabricated in a highly multiplexed manner. | 2008-10-02 |
| 20080242562 | APPARATUS AND METHODS FOR DETECTING NUCLEIC ACID IN BIOLOGICAL SAMPLES - There are disclosed apparatus and methods for the field-assisted acceleration of biological processes involving charged entities, including in particular the detection of target DNA in a biological sample. A reaction cell is provided with a dielectric surface, and a field is generated by inducing charge-separation in the dielectric material by applying a potential to an electrode in contact with the dielectric material. | 2008-10-02 |
| 20080242563 | Zirconium-based cross-linker compositions and their use in high pH oil field applications - A cross-linking composition which comprises (a) an aqueous liquid, (b) a cross-linkable organic polymer, and (c) a solution comprising a zirconium cross-linking agent which comprises a zirconium complex having a molar ratio of 1:2 to 1:4 of zirconium to triethanolamine and a molar ratio of 1:0.1 to 1:1 of zirconium to N,N,N′,N′-tetrakis-(2-hydroxypropyl)-ethylene diamine. The composition can be used in oil field applications for hydraulic fracturing and plugging of permeable zones and leaks in subterranean formations. | 2008-10-02 |
| 20080242564 | Method for improving the cooling efficiency of a functional fluid - A method is disclosed for improving the cooling of equipment lubricated by functional fluids, such as power train fluids, by lubricating the equipment with a functional fluid comprising a wax isomerate or hydrodewaxate base stock and at least one performance additive thus permitting a reduction in the volume of lubricant used and a concomitant reduction in the size of the lubricant reservoir and related equipment. | 2008-10-02 |
| 20080242565 | Novel Cherkasky Lubricants Based On Modified Biomolecules and Biomasses, Methods For Their Production And Use of Modified Biomolecules And Biomasses As Lubricants or Additives - Both prepared, non-chemically modified and chemically modified biomasses, preferably algal biomasses as well as proteins and nucleic acids and organelles will be used either as lubricants or additives to lubricants. The advantages are as follows: the utility or utilization of biomasses such as dead animal bodies or plant and algal biomasses on the sea shores, for example during tides, the use of renewable row materials as lubricants and additives to other lubricants, the economical use of other lubricants, especially of those based on fossil sources, as well as the improvement of lubricative features by adding to oils, fats and pastes as well as the use of the lubricants according to this invention as an alternative to current lubricants. Modified biomolecules can improve thereby the quality of lubricants. | 2008-10-02 |
| 20080242566 | GEAR OIL COMPOSITION CONTAINING NANOMATERIAL - The present invention relates to a novel use of nanomaterials as a viscosity modifier and thermal conductivity improver for gear oil and other lubricating oil compositions. The gear oils of the instant invention have a higher viscosity index, higher shear stability, and improved thermal conductivity compared to currently available gear oils. The preferred nanoparticles also impart a reduction in the coefficient of friction, including reduced friction in the boundary lubrication regime. These properties are obtained by replacing part or all of the polymer thickener or viscosity index improver or some other part of the composition normally used in gear oils with nanomaterials of suitable shape, size, and composition. | 2008-10-02 |
| 20080242567 | LUBRICANT FOR CONVEYOR CHAINS - A lubricant for conveyor chains, the lubricant consists of a mixture of a quantity of fatty acid, a quantity of amine, a quantity of polyglycol, and a quantity of hydrocarbon. The lubricant of the invention uses a direct application, without dilution, and forms a layer or film of lubricant on the surface of the conveyor chain so that the application is discontinued, in long intervals between the applications. | 2008-10-02 |
| 20080242568 | Method for improving the air release rate of GTL base stock lubricants using synthetic ester, and composition - A method for improving the air release rate of a Gas-to-Liquids (GTL) base stock and/or base oil by the addition to such base stock and/or base oil of a synthetic ester. | 2008-10-02 |
| 20080242569 | LIQUID DETERGENT COMPOSITION SYSTEM HAVING A VISUAL INDICATION CHANGE - A detergent composition with a pH of 7.5 to 13 having a pH dye and a sulfate or sulphonate surfactant that changes color when added to a volume of water such that a blue or green color results from the dilution of the detergent composition. | 2008-10-02 |
| 20080242570 | LIQUID COMPOSITION SYSTEM HAVING A VISUAL INDICATION CHANGE - A detergent composition having a pH dye and an amphoteric surfactant that changes color when added to a volume of water. | 2008-10-02 |
| 20080242571 | Oil Containing Starch Granules For Delivering Benefit-Additives to a Substrate - An oil containing starch granule is provided comprising:
| 2008-10-02 |
| 20080242572 | Detergent Printed Film - The present invention discloses a water-soluble detergent printed film comprising a film support and at least one print, being printed thereon and/or therein said film, said film is a water-soluble detergent adapted for effective cleansing of various human body and goods cleaning. The present invention also discloses a method of producing a water-soluble detergent printed film, comprising forming a detergent film; and, printing the same with at least one print. | 2008-10-02 |
| 20080242573 | MULTIPHASE PERSONAL CARE COMPOSITION COMPRISING A STRUCTURING SYSTEM THAT COMPRISES AN ASSOCIATIVE POLYMER, A LOW HLB EMULSIFIER AND AN ELECTROLYTE - The present invention relates to a multiphase personal care composition. The multiphase personal care composition comprises an aqueous structured surfactant phase, a structuring system, and a benefit phase. The aqueous structured surfactant phase comprises from about 5% to about 16%, by weight of the multiphase personal care composition, of a lathering surfactant selected from the group consisting of anionic surfactants, nonionic surfactants, amphoteric surfactants, cationic surfactants or mixtures thereof and a structuring system. The structuring system comprises a non-ionic emulsifier having an HLB of from about 1.4 to about 13; about 0.05% to about 5%, by weight of the multiphase personal care composition, of an associative polymer; and an electrolyte. The benefit phase comprises from about 5% to about 30%, by weight of the multiphase personal care composition, of hydrophobic benefit material. | 2008-10-02 |
| 20080242574 | Metal and Dielectric Compatible Sacrificial Anti-Reflective Coating Cleaning and Removal Composition - A liquid removal composition and process for removing sacrificial anti-reflective coating (SARC) material from a substrate having same thereon. The liquid removal composition includes at least one fluoride-containing compound, at least one organic solvent, optionally water, and optionally at least one chelating agent. The composition achieves at least partial removal of SARC material in the manufacture of integrated circuitry with minimal etching of metal species on the substrate, such as aluminum, copper and cobalt alloys, and without damage to low-k dielectric materials employed in the semiconductor architecture. | 2008-10-02 |
| 20080242575 | Treating liquid for photoresist removal, and method for treating substrate - Disclosed are a treating liquid for photoresist removal, containing (a) an oxidizing agent (e.g., aqueous hydrogen peroxide), (b) at least one selected from alkylene carbonates and their derivatives (e.g., propylene carbonate), and (c) water; and a method for treating with the treating liquid a substrate having a photoresist film deteriorated after dry-etching treatment thereof or a substrate optionally subjected to plasma-ashing treatment after the dry-etching treatment, and then treating it with a photoresist-stripping liquid for stripping off the photoresist. | 2008-10-02 |
| 20080242576 | Probe cleaning sheet - A probe cleaning sheet for removing foreign objects attached to tip part of a probe is formed with a plastic sheet having a flat and even surface and a uniform thickness and a cleaning layer with a flat and even surface and a uniform thickness formed on the surface of this plastic sheet. The cleaning layer has viscoelastic properties. Its Young's modulus is 30 MPa or more and 700 MPa les less, its storage modulus at 25° C. is 1.2×10 | 2008-10-02 |
| 20080242577 | Clear Rinsing Agent Containing Hydrophobically Modified Polycarboxylates - Rinse agent formulations for machine dishwashing, comprising as components:
| 2008-10-02 |
| 20080242578 | Oil Containing Starch Granules For Delivering Benefit-Additives to a Substrate - An oil containing starch granule is provided comprising: | 2008-10-02 |
| 20080242579 | Laundry Product - A unit dose fabric treatment system comprises a water soluble container in which a liquid fabric treatment composition is disposed, the composition comprising one or more fatty acid esters wherein, in at least one of the fatty acid esters, the average proportion of C18 chains is less than 60%, preferably less than 50%, more preferably less than 40%, e.g. less than 30% by weight of the total weight of fatty acid chains in the fatty acid ester. | 2008-10-02 |
| 20080242580 | Method of Preparing a Laundry Product - A method of preparing a composition for use in a unit dose fabric treatment system, the method comprising the steps of reacting together, in the presence of water, a ester-containing soap precursor, a base material, and optionally a solvent. | 2008-10-02 |
| 20080242581 | Liquid Detergent With Refractive Particle - A liquid detergent composition containing refractive particles. | 2008-10-02 |
| 20080242582 | COMPOSITIONS CONTAINING BENEFIT AGENT COMPOSITES PRE-EMULSIFIED USING COLLOIDAL CATIONIC PARTICLES - A cleansing or a surface-conditioning composition comprising a mixture of (i) and (ii) in water: i) a surfactant selected from the group consisting of anionic, non-ionic, zwitterionic, cationic, and mixtures thereof, and ii) a hydrophobic benefit agent in a particulate form having a mean particle size in the range of 1-1,000 micron, and a specific gravity of ≧1, not encapsulated within a film or a capsule-like enclosure, the particulate hydrophobic benefit agent comprising: a) a physically-modified form of the hydrophobic benefit agent; and b) a deposition-aid material bonded to the surface of the physically-modified benefit agent material, wherein the bonding between the two said materials is achieved prior to addition to i), wherein said deposition-aid material is not a surfactant having a weight average molecular weight of less than 5,000 Dalton. | 2008-10-02 |
| 20080242583 | Composition and Method - A cleaning composition comprising at least 80 percent by water at least 1 percent by weight of an amphiphile, and at least 0.005 percent by weight of hydrocarbon exhibits good cleaning performance and a visual indication of activity. The composition is on or adjacent to a phase boundary of its phase diagram and exhibits self-induced surface motility of the Marangoni type. | 2008-10-02 |
| 20080242584 | Fabric care composition - A fabric enhancer composition comprising: (a) a cationic polymer; (b) less than about 20% silicone; and (c) a deposition aid; wherein the composition is essentially free of a coacervate. | 2008-10-02 |
| 20080242585 | Disubstituted Tetrathianes as Fragrances or Flavourings | 2008-10-02 |
| 20080242586 | ORGANOLEPTIC COMPOUNDS AND THEIR USE IN PERFUME COMPOSITIONS - The present invention is directed to the novel compounds of the general formula | 2008-10-02 |
| 20080242587 | FUSION PROTEINS BINDING TO VEGF AND ANGIOPOIETIN - The present application discloses an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and Angiopoietin polypeptide, which includes a nucleotide sequence encoding a Tie2 component and a VEGFR component. | 2008-10-02 |
| 20080242588 | SYSTEM FOR SEIZURE SUPPRESSION - Systems, including methods and compositions, for seizure suppression, such as inhibition of epileptic seizures. In some embodiments, the methods may provide a screen for anti-seizure drugs. One or more compositions may be selected based on an ability to affect a response of biological cells to a change in extracellular pH and/or to affect an activity of at least one acid sensing ion channel (ASIC). Based on the one or more compositions selected, at least one drug candidate may be assayed for inhibition of seizure-like electrical activity and/or seizures. In some embodiments, the methods and compositions may, respectively, administer and provide an effective amount of PcTX1, a peptide derivative of PcTX1 amiloride, an amiloride derivative, or a combination thereof to a subject prone to seizures and/or having a seizure, in order to suppress seizure activity. | 2008-10-02 |
| 20080242589 | SYNTHETIC LIPID MIXTURES FOR THE PREPARATION OF A RECONSTITUTED SURFACTANT - The invention relates to reconstituted surfactants consisting of artificial phospholipids and peptides able to lower the air-liquid surface tension, more particularly to reconstituted surfactants comprising special phospholipid mixtures and artificial peptides which are analogues of the natural surfactant SP-C protein for the treatment of respiratory distress syndrome (RDS) and other diseases relating to pulmonary surfactant dysfunctions. | 2008-10-02 |
| 20080242590 | New Method 706 - The present invention relates fusion proteins and their use in enzymatic treatment of Alzheimer's disease patients. Said fusion protein has the formula M-A, capable of degrading amyloid beta peptide at one or more cleavage sites in its amino acid sequence, wherein M is a protein component that prolongs the half-life of the fusion protein, and A is a protein component that cleaves the amyloid beta peptide. | 2008-10-02 |
| 20080242591 | METHODS OF REDUCING ANGIOGENESIS - The present invention provides methods of reducing angiogenesis in an individual. The methods generally involve administering to the individual an effective amount of a nicotinic acetyl choline receptor antagonist. The methods are useful to treat conditions associated with or resulting from angiogenesis, particularly pathological angiogenesis. The invention further provides methods of treating a condition associated with or resulting from angiogenesis. | 2008-10-02 |
| 20080242592 | METHOD FOR CONTROLLING BODY WEIGHT IN ESTROGEN-INSUFFICIENT WOMEN - Disclosed are methods of controlling body weight in estrogen-insufficient women by administering compositions comprising (A) those dried fruit solids that inherently comprise flavonoids, hydroxycinnamic acids, and a fiber component of which at least about 20% by weight is soluble fiber, and (B) a soluble, indigestible oligosaccharide in addition to any soluble fiber inherently in the dried fruit solids. The dried fruit solids may also be characterized as those selected from dried plum, dried grape, dried date, or dried fig. Administration of dried fruit solids (e.g., dried plum solids) in combination with soluble indigestible oligosaccharides (e.g., fructooligosaccharides) are surprisingly effective in controlling body weight gain in estrogen-insufficient women. | 2008-10-02 |
| 20080242593 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS - The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The peptides of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes. | 2008-10-02 |
| 20080242594 | Methods for Promoting Stem Cell Proliferation and Survival - It is disclosed herein that STAT3 phosphorylated at serine 727 is a key regulator of proliferation and survival of stem cells and precursor cells. Methods for increasing the survival and proliferation of stem cells and/or precursor are disclosed herein. In one embodiment, the method includes contacting a mammalian stem cell mammalian precursor cell with a JAK inhibitor, a p38 inhibitor, or both. Methods are also disclosed for increasing the survival and proliferation of neuronal precursor cells in a subject. The method includes administering a therapeutically effective amount of a Notch ligand and a growth factor. Methods are also disclosed for identifying an agent that increases the proliferation of stem cells and/or precursor cells. The method includes contacting a stem cell or a precursor cell with an agent of interest, wherein the stem cell or the precursor cell expresses STAT3; and determining the phosphorylation status of serine 727 of STAT3 in the cell. Phosphorylation of serine 727 indicates that the agent increases the survival and/or proliferation of stem cells and/or precursor cells. An isolated population of cells is disclosed, wherein the cells express nestin and STAT3, wherein serine 727 of STAT3 is phosphorylated. | 2008-10-02 |
| 20080242595 | Conjugate of insulin and vitamin B12 for oral delivery - Compositions containing a therapeutic peptide covalently linked to Vitamin B | 2008-10-02 |
| 20080242596 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE - Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition. | 2008-10-02 |
| 20080242597 | Antibiotic compounds - The present invention relates to novel thiazolyl peptide antibiotics capable of treating serious bacterial infections in mammals, and particularly, in humans. Some of the analogs can also be versatile intermediates for the preparation of new derivatives with useful antibacterial activity. | 2008-10-02 |
| 20080242598 | Alpha Helical Mimics, Their Uses and Methods For Their Production - This invention discloses short chain peptides that have been constrained to adopt an alpha helical conformation and their use as alpha helical scaffolds for directing amino acid side chains into positions analogous to those found in longer chain alpha helical peptides and for attaching peptidic or non-peptidic appendages in order to mimic side chains of longer alpha helical peptides. More particularly the invention discloses alpha helical cyclic pentapeptides and their use as alpha helical scaffolds or macrocyclic alpha helical modules, either alone, or within longer chain peptides or attached to other macrocyclic peptides or attached to non-peptidic structures, for the purpose of mimicking naturally occurring peptides or proteins, and as agonists or antagonists of the biological activity of naturally-occurring peptides or proteins or for the preparation of new materials. | 2008-10-02 |
| 20080242599 | Compositions and Methods for Increasing Osteoblast Cell Differentiation and Bone Generation - The present invention relates to the discovery of a novel pathway for the induction of osteoblast cellular differentiation and bone generation. Specifically, the present invention envisions a novel screening tool for the determination of compounds capable of promoting osteoblast cellular differentiation that could be used in the treatment of various bone-loss or bone density decreasing disorders. The method of screening of the present invention enables one to determine whether a compound affects certain pathways that promote via direct induction, or the downregulation of inhibiting activity, the differentiation of progenitor cells into osteoblasts. This promotion of osteoblasts could provide for treatments for bone-loss or bone density disorders. The invention further encompasses methods of increasing bone density using the compounds, the compounds, and pharmaceutical compositions comprising the compounds. | 2008-10-02 |
| 20080242600 | Backbone Cyclized Melanocortin Stimulating Hormone (Alpha Msh) Analogs - Backbone cyclized peptides which are α-melanocortin stimulating hormone (αMSH) analogs, having improved Melanocortin-4 receptor agonist activity are disclosed. The backbone cyclized peptide analogs disclosed possess unique and superior properties over other analogs, such as metabolic stability, increased oral bioavailability, improved intestinal permeability and pharmacological activity in-vivo. Pharmaceutical compositions that include the backbone cyclized αMSH analogs, and methods of using such compositions for the treatment of metabolic disorders including obesity are also disclosed. | 2008-10-02 |
| 20080242601 | Selective Inhibition of Nf-Kappab Activiation by Peptides Designed to Disrupt Nemo Oligomerization - The present invention relates to polypeptides that inhibit the NF-&kgr; B signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO. | 2008-10-02 |
| 20080242602 | Methods and Compositions For the Inhibition of Hiv-1 Replication - This invention relates to methods and compositions for the attenuation of HIV-1 replication in human cells, and especially in human macrophages. The invention particularly concerns the use of inhibitors of P21 (CDKN1A) expression to attenuate such replication. The invention particularly concerns the use of antisense P21 oligonucleotides, siRNA and/or 2-cyano-3,12-dioxooleana-1,9-dien28-oic (CDDO) to attenuate such replication. | 2008-10-02 |
| 20080242603 | Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use - Disclosed are newly identified Interleukin 24 and APO2L splice variant molecules, their polypeptide sequences, and the polynucleotides encoding the polypeptide sequences. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells, and, for example, heterologous secretory leader sequences. Also disclosed are methods for using such polypeptides and modulators thereof for the treatment of diseases, including cancer, immune diseases, infectious diseases, and ischemic diseases. | 2008-10-02 |
| 20080242604 | Human Nodal and Lefty Homologues - The present invention relates to novel Nodal and Lefty proteins which are members of the TGF-β family. In particular, isolated nucleic acid molecules are provided encoding the human Nodal and Lefty proteins. Nodal and Lefty polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Nodal and Lefty activity. Also provided are diagnostic methods for detecting cell growth and differentiation-related disorders and therapeutic methods for treating cell growth and differentiation-related disorders. | 2008-10-02 |
| 20080242605 | CHEMOTAXIS-INHIBITING PROTEIN OF STAPHYLOCOCCUS (CHIPS) AND ITS USE - The present invention relates to a new protein of the bacteria | 2008-10-02 |
| 20080242606 | Use of IMP3 as a Prognostic Marker for Cancer - Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided. | 2008-10-02 |
| 20080242607 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES - The present invention provides sequon polypeptides with an amino acid sequence including one or more exogenous O-linked glycosylation sequence of the invention. In addition, the present invention provides methods of making polypeptide conjugates as well as methods of using such conjugates and their pharmaceutical compositions. The invention further provides libraries of sequon polypeptides, wherein each member of such library includes at least one exogenous O-linked glycosylation sequence of the invention. Also provided are methods of making and using such libraries. | 2008-10-02 |
| 20080242608 | Methods and compositions for treating and preventing neurologic disorders - The present invention provides methods for treating or reducing neurologic and ischemic vascular disorders. | 2008-10-02 |
| 20080242609 | Composition for the therapy of diabetes mellitus and adiposity - A composition containing at least two of the following active substances A, B, C, wherein: | 2008-10-02 |
| 20080242610 | POLYPEPTIDES COMPRISING FAS ACTIVATION AND NKG2D-LIGAND DOMAINS - The present invention is drawn to fusion proteins comprising (a) a ligand for an NK receptor and (b) a Fas activation domain, and to nucleic acids encoding such fusion proteins. The invention also includes methods of making and using such proteins and nucleic acids, including their use in preventing or treating cancer. | 2008-10-02 |
| 20080242611 | TGF-Alpha POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR - Disclosed are TGF-α polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex vivo and in vivo applications. | 2008-10-02 |
| 20080242612 | ADMINISTRATION OF LEPTIN - A method and composition for administering leptin to a subject. The invention includes suspending isolated native leptin-containing milk fat globules in a suitable medium for administering to a subject. The suspended milk fat globules may be administered orally as well as by intravenous, intramuscular, intraperitone41, other enteral routes of administration, and other parenteral routes of administration. The invention includes a method for treating growth or maturational-related disorders in newborns as, well as subjects having conditions that can be treated by the administration of leptin. | 2008-10-02 |
| 20080242613 | BIOACTIVE PARSTATIN PEPTIDES AND METHODS OF USE - Bioactive peptides that have a molecular weight of approximately 4.5 kDa and correspond to amino-terminal fragments of protease-activated receptor-1 (PAR-1), which are cleaved and released upon the proteolytic activation of PAR-1 by proteases including, but not limited to, thrombin in humans and animals are disclosed. Such synthetic or recombinantly expressed or endogenously produced or chimeric synthetic peptides that are active in vitro and in vivo and modulate endothelial cell functions and physiological and pathological processes are named herein as parstatin. Parstatin peptides, fragments, analogs, derivatives have the ability to inhibit endothelial cell growth, migration and differentiation, to induce endothelial cell apoptosis, to block angiogenesis and have cardioprotective effects in ischemia/reperfusion injury. Methods for treating angiogenesis-related diseases and endothelium dysfunction-related cardiovascular diseases are disclosed. | 2008-10-02 |
| 20080242614 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN - Compositions and methods for treating infections, especially bacterial infections, are provided. Indolicidin peptide analogues containing at least two basic amino acids are prepared. The analogues are administered as modified peptides, preferably containing photo-oxidized solubilizer. | 2008-10-02 |
| 20080242615 | SURFACTANT PROTEIN-D FOR PREVENTION AND TREATMENT OF LUNG INFECTIONS AND SEPSIS - Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Administration of SP-D protein or fragments thereof is useful for the prevention or treatment of sepsis or lung infection. | 2008-10-02 |
| 20080242616 | PEPTIDE SPECIFICITY OF ANTI-MYELIN BASIS PROTEIN AND THE ADMINISTRATION OF MYELIN BASIC PROTEIN PEPTIDES TO MULTIPLE SCLEROSIS PATIENTS - Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire length of the protein have been produced. Antibodies to h-MBP (anti-MBP) were found to be neutralized by the synthetic peptides, in vitro, which span the h-MBP from about amino acid residue 61 to about amino acid residue 106. The peptides, which cover both the amino (about residues 1 to 63) and carboxy (about residues 117 to 162) terminals of h-MBP did not neutralize purified anti-MBP. Intrathecal administration of peptide MBP(75-95), MBP(86-95), or MBP(82-98) produced complete binding-neutralization of free (F) anti-MBP with no change in bound (B) levels. A control peptide MBP35-58 had no effect on F or B anti-MBP levels. Intravenous administration of MBP(75-95), MBP(86-95), or MBP(82-98) resulted in significant decline of F and B CSF anti-MBP levels. Administration of MBP synthetic peptides to MS patients either intrathecally or intravenously did not have any adverse neurological effects and systemic complications did not occur. The MBP epitope for MS anti-MBP has been localized to an area between amino acid 86 and amino acid 95. | 2008-10-02 |
| 20080242617 | Two component bacillus lantibiotic and methods for producing and using the same - The present invention relates to two-component lantibiotics isolated from | 2008-10-02 |
| 20080242618 | Stratification - Provided is the use of a gene-regulatory peptide or functional analogue thereof for the treatment of a disease comprising an inflammatory condition and/or a counter-inflammatory condition wherein a subject suffering from the disease is subjected to a diagnostic process aimed at determining inflammatory disease stage of the subject and where treatment is selected depending on the outcome of the determination of disease stage. | 2008-10-02 |
| 20080242619 | Growth hormone releasing peptides - Disclosed are peptide and peptidomimetic compounds generally according to formula (I), and pharmaceutically acceptable salts thereof, that are useful as GHRP analogs: R | 2008-10-02 |
| 20080242620 | Biologically active peptide comprising tyrosyl-seryl-valine (YSV) - The tripeptide Tyrosyl-seryl-valine is disclosed with its use as a pharmaceutical composition. A method is also disclosed making a pharmaceutical composition comprising providing the tripeptide Tyrosyl-seryl-valine and mixing said tripeptide with a pharmaceutical acceptable carrier. | 2008-10-02 |
| 20080242621 | YEAST HYDROLYSATE CONTAINING CYCLO-HIS-PRO AND METHOD OF MAKING AND USING THE SAME - Provided is a method for producing a yeast hydrolysate containing Cyclo-His-Pro (CHP), via an enzyme-substrate reaction by addition of a flavourzyme to a yeast suspension. Herein, the yeast hydrolysate obtained after the enzyme-substrate reaction is filtered or centrifuged to recover a supernatant, and the supernatant may be subjected to (1) drying after ultrafiltration, or (2) drying after activated carbon treatment, or (3) combined treatment of (1) and (2). The method of the present invention enables production of the yeast hydrolysate having a remarkably high content of Cyclo-His-Pro (CHP), as compared to conventional foods. In particular, purification of the thus-resulting yeast hydrolysate can enhance the content of Cyclo-His-Pro (CHP) 10-fold to 85-fold higher than prior to the purification thereof. The yeast hydrolysate containing Cyclo-His-Pro (CHP) of the present invention exerts blood glucose-lowering effects and glucose tolerance-improving effects, simultaneously with an enhancement of insulin sensitivity. | 2008-10-02 |
| 20080242622 | Identification of genetic alterations that modulate drug sensitivity in cancer treatments - This invention features methods of identifying genetic alterations that can modulate cancer cells' sensitivity to an anti-cancer drug. Information on such genetic alterations can be used to predict cancer therapeutic outcomes and to stratify patient populations to maximize therapeutic efficacy. | 2008-10-02 |
| 20080242623 | Microutrophin and Uses Thereof - A microutrophin containing a utrophin having internal deletions (relative to a native utrophin) in the hinge regions and a C-terminal deletion is provided. Also provided are vectors and compositions useful for delivering the microutrophin for the treatment of muscular disorders, including Duchenne Muscular Dystrophy. | 2008-10-02 |
| 20080242624 | Cyclin D Polynucleotides, Polypeptides and Uses Thereof - The invention provides isolated polynucleotides, specifically Cyclin D polynucleotides, and their encoded proteins that are involved in cell cycle regulation. The invention further provides recombinant expression cassettes, host cells, transgenic plants, and antibody compositions. The present invention provides methods and compositions relating to altering cell cycle protein content and/or composition of plants for the purpose of increasing transformation efficiency. | 2008-10-02 |
| 20080242625 | Nucleotide-Cochleate Compositions And Methods Of Use - The present invention is directed to cochleate composition that include a nucleotide. The nucleotide may generally be bound via a linker to a component of the cochleate, or to a lipophilic tail. Additionally or alternatively, the nucleotide may be associated with a transfection agent. The present invention also includes methods for making and using the compositions provided herein. | 2008-10-02 |
| 20080242626 | End-Modified Poly(beta-amino esters) and Uses Thereof - Poly(beta-amino esters) are end-modified to form materials useful in the medical as well as non-medical field. An amine-terminated poly(beta-amino ester) is reacted with an electrophile, or an acrylate-terminated poly(beta-amino ester) is reacted with a nucleophile. The inventive end-modified polymers may be used in any field where polymers have been found useful including the drug delivery arts. The end-modified polymers are particularly useful in delivery nucleic acids such as DNA or RNA. The invention also provides compositions including the inventive end-modified polymers, methods of preparing the inventive polymers, and method of using the inventive polymers. | 2008-10-02 |
| 20080242627 | NOVEL RNA INTERFERENCE METHODS USING DNA-RNA DUPLEX CONSTRUCTS - The present invention provides novel compositions and methods for suppressing the function or activity of a targeted gene through a novel intracellular piRNA-mediated RNAi mechanism, using RNA-DNA duplex constructs. The invention further provides novel methods and compositions for generating or producing RNA-DNA duplex agents, whose quantity is high enough to be used for the invention's gene silencing transfection and possibly in therapeutics applications. This improved RNA-polymerase chain reaction (RNA-PCR) method utilizes thermocycling steps of promoter-linked DNA or RNA template synthesis, in vitro transcription and then reverse transcription to bring up the amount of RNA-DNA duplexes up to two thousand folds within one round of the above procedure for using in D-RNAi-directed gene silencing. | 2008-10-02 |
| 20080242628 | Inhibiting Gene Expression with dsRNA - The present invention relates to the specific inhibition of gene expression in mammals by bringing the target gene into contact with double stranded RNA (dsRNA). | 2008-10-02 |
| 20080242629 | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION - Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided. | 2008-10-02 |
| 20080242630 | Fusion proteins of mycobacterium tuberculosis - The present invention relates to compositions and fusion proteins containing at least two | 2008-10-02 |
| 20080242631 | Impaired wound healing compositions and treatments - Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods, compositions and articles. | 2008-10-02 |
| 20080242632 | MULTI-TARGETING SHORT INTERFERING RNAs - The present invention relates to novel short interfering RNA (siRNA) molecules that are multi-targeted. More specifically, the present invention relates to siRNA molecules that target two or more sequences. In one embodiment, multi-targeting siRNA molecules are designed to incorporate features of siRNA molecules and features of micro-RNA (miRNA) molecules. In another embodiment, multi-targeting siRNA molecules are designed so that each strand is directed to separate targets. | 2008-10-02 |
| 20080242633 | Methods of modulating apoptosis and platelet production using variants of cytochrome c - The invention relates to a method for using the gene or protein containing CYCS(Gly42-Ser) to enhance cellular apoptosis. The method can be used to modulate apoptosis to treat conditions associated with an abnormal rate of apoptosis, in particular to treat conditions associated with increased cell growth, for example hyperplasia, hypertrophy, cancer, neoplasia or the like. The invention also relates to the use of the gene or protein containing CYCS(Gly42-Ser) for stimulating platelet release from megakaryocytes, and also to the treatment of thrombocytopenia using the platelets. | 2008-10-02 |
| 20080242634 | Treatment for neuropathic pain due to spinal cord injury - The present invention is drawn to treatment of neuropathic pain due to spinal cord injury. In this regard, the present invention discloses methods and composition to treat neuropathic pain. | 2008-10-02 |
| 20080242635 | Method for Lengthening the Seasonal Mobility Period of Fish - This invention is in the field of animal feed, more in particular in the field of fish feed. Surprisingly, it has been found that the seasonal mobility period of fish may be lengthened by interfering with the diet of the fish. We found that it is possible to increase the seasonal mobility period of fish to such an extent that it is even active at temperatures as low as 2 degrees Celsius. Such may be accomplished by adding naturally occurring substances to the feed of the fish. Examples of these naturally occurring substances are immune enhancing ingredients like beta-glucans and/or small amounts of phytohormones like auxin or gibberellic acid. Also, combinations of these substances, in particular the combination of beta-glucans and phytohormones, were shown to have a synergistic effect in that they lengthened the seasonal mobility period of the fish more than the individual components on their own. | 2008-10-02 |
| 20080242636 | MODIFIED CYCLODEXTRIN SULFATE-71 (TERIGYN) AS A MICROBICIDE AGENT - A method of reducing human immunodeficiency virus infective events by applying terygyn and a suitable excipient formulated for topical administration to the vaginal, anal, urethral or penile glans mucosa of an individual prior to or subsequent to infection by human immunodeficiency virus is herein described. | 2008-10-02 |
| 20080242637 | Use of Cytochrome P450 Enzyme CYP2WI as a Drug Target for Cancer Therapy - The present invention relates to a novel drug target in cancer therapy. More closely it relates to use of the cytochrome P450 enzyme CYP2W1 and its promoter as a drug target for cancer therapy. It also relates to screening methods for obtaining therapeutic agents for cancer therapy and to therapeutic agents comprising moieties showing binding affinity for CYP2W1 and moieties with cytotoxic/anti-cancer effect. | 2008-10-02 |
| 20080242638 | INDUCTION OF DIFFERENTIAL STRESS RESISTANCE AND USES THEREOF - This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents. | 2008-10-02 |
| 20080242639 | Phosphagen Synthesis - Cyclocreatine phosphate can be prepared in large quantities from inexpensive starting materials to afford a stable product. | 2008-10-02 |
| 20080242640 | Surfactant Lipids, Compositions Thereof and Uses Thereof - The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions. | 2008-10-02 |
| 20080242641 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 2008-10-02 |
| 20080242642 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 2008-10-02 |
| 20080242643 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5H)-Furanones as Cyclooxygenase-2 Inhibitors - The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H)-furanones useful in the treatment of cyclooxygenase-2 mediated diseases. Formula (I). The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula 1. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events. | 2008-10-02 |
| 20080242644 | Factor Viia Inhibitor - The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed. | 2008-10-02 |
| 20080242645 | COSMETIC COMPOSITION - The invention relates to a composition containing, preferably in a physiologically acceptable medium, at least one xanthine base or a plant extract containing it, at least one polyurethane powder, and at least one non-ionic dimethicone copolyol. The invention also relates to a cosmetic method for combating cellulite and/or “orange-peel” skin and/or slimming the figure, comprising the application of the composition to the skin. The composition applied to the skin exhibits good cosmetic properties of softness and of non-tackiness. | 2008-10-02 |
| 20080242646 | Split dose corticosteroid therapy - The invention features methods, compositions, and kits for split dose corticosteroid therapy for the treatment musculoskeletal disorders, periodontal disease, and immunoinflammatory disorders. | 2008-10-02 |
| 20080242647 | Use of Molt-Accelerating Compounds, Ecdysteroids, Analogs Thereof, and Chitin Synthesis Inhibitors for Controlling Termites - The subject invention relates in part to the oral administration of ecdysteroids for controlling subterranean termites. Preferred ecdysteroids for use according to the subject invention are ecdysone, certain ecdysone analogs, and 20-hydroxyecdysone, for example. In some preferred embodiments, one or more of these compounds is used in a termite bait in combination with one or more chitin synthesis inhibitors (CSI), such as hexaflumuron and/or noviflumuron. The subject invention also relates to mixtures comprising these two active ingredients. The ecdysteroid analog or molt-accelerating compound (MAC) typically induces a preliminary molting event in termite workers, which then allows the CSI to further disrupt the molt and cause mortality. The combination of these active ingredients, causing accelerated molting together with inhibition of chitin synthesis, is surprisingly shown herein to enhance activity against termites, as compared to either group of compounds alone. | 2008-10-02 |
| 20080242648 | COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER - The present embodiments relate to compositions and methods of treatment of cancer. More particularly, the present embodiments relate to the combination of an ERα+ ligand with an HDACi for the treatment of cancer, methods of treating cancer and pharmaceutical compositions for treating cancer. | 2008-10-02 |
| 20080242649 | New Combination 665 - The invention provides a pharmaceutical product comprising a first active ingredient which is N—[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist which is Aclidinium bromide, Glycopyrrolate, Oxitropium bromide, Pirenzepine, telenzepine, Tiotropium bromide, 3(R)—(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide, 3(R)—1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane bromide or (3R)—3-[(2S)—2-cyclopentyl-2-hydroxy-2-thien-2-ylacetoxy]-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]actane bromide; a p38 inhibitor; a PDE inhibitor; a PPARγ agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease. | 2008-10-02 |
